Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations
Status:
Recruiting
Trial end date:
2023-02-02
Target enrollment:
Participant gender:
Summary
This is a Phase 4, open label, single arm, multi-center, prospective clinical trial of
dacomitinib that will be performed in India. This study will enroll a sufficient number of
participants to ensure that 100 participants are treated with dacomitinib. The primary
objective of this study is to assess the safety and tolerability of dacomitinib. The
secondary objective is to evaluate antitumor activity of dacomitinib by objective response
rate and duration of response.